Takeda and TiGenix report positive data for Crohn’s disease therapy

Takeda and TiGenix have announced new clinical trial data showing the strong performance of their investigational compound Cx601 in the treatment of Crohn's disease.

The suspension of allogeneic adipose-derived stem cells was shown to help maintain long-term remission of treatment-refractory complex perianal fistulas in patients with Crohn's disease over a 52-week therapy period in the ADMIRE-CD trial.

Data from this phase III trial will help to support the companies' application for regulatory approval of the drug in Europe, with the European Commission having already granted Cx601 orphan drug designation.

A decision from the European Medicines Agency is expected at some point this year. Another phase III trial will also be launched in 2017 to help secure regulatory approval from the US Food and Drug Administration.

Dr Asit Parikh, head of Takeda's gastroenterology therapeutic area unit, said: "Existing therapies are limited and associated with complications and a high failure rate. Cx601 may offer patients an alternative treatment option."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.